NCT03808532 (ACE-AD) is a Phase 2 clinical trial of Cura+ Moisturizing Cream in Dermatitis, Atopic, sponsored by MYOR Ltd..

Who is sponsoring NCT03808532?

NCT03808532 is sponsored by MYOR Ltd..

What drugs are being tested in NCT03808532?

Interventions in NCT03808532: Cura+ Moisturizing Cream.

What condition does NCT03808532 study?

NCT03808532 studies Dermatitis, Atopic.

Is NCT03808532 still recruiting?

NCT03808532 is currently withdrawn. Last updated 13 January 2021.

Last reviewed 2021-01-13 · How we verify

NCT03808532: ACE-AD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective Randomized Open-label Controlled Study to Assess Whether Daily Application of Skin Moisturizer Containing Acemannan Hydrogel From Birth Can Prevent Atopic Dermatitis in Children

Withdrawn Phase 2 Last updated 13 January 2021

What this trial tests

Phase 2 trial testing Cura+ Moisturizing Cream in Dermatitis, Atopic. Withdrawn.

Timeline

1 June 2020

Primary endpoint
1 December 2021

1 December 2022

Quick facts

Lead sponsor	MYOR Ltd.
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Start date	1 June 2020
Primary completion	1 December 2021
Estimated completion	1 December 2022

Drugs / interventions tested

Cura+ Moisturizing Cream

Conditions studied

Dermatitis, Atopic — all drugs for Dermatitis, Atopic →

Sponsor

MYOR Ltd.

Who can join

Adults 24 Hours to 120 Hours, any sex, with Dermatitis, Atopic. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cumulative incidence of AD at twelve months of age in the intervention group compared to the control
Time frame: 12 months
Evaluated using the UK refinement of the Hanifin and Rajka diagnostic criteria for atopic eczema and by parental report of a medical diagnosis of AD by the infant's pediatrician and/or dermatologist

Sponsor's own description

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder associated with a decreased ability of the skin to function as an efficient immunological barrier. The disease is now two to three times more prevalent in children than it was just four decades ago. It is manifested by eczematous skin lesions associated with severe itch, leading to a significant impairment in quality of life. Of additional importance, AD oftentimes progresses to allergic rhinitis and/or asthma, a process referred to as the "atopic march." Recent reports have indicated that daily application of moisturizing creams on neonates and infants can prevent the occurrence of AD and subsequently food allergies. This is postulated to be the outcome of restoring the barrier integrity of the skin through the daily application of moisturizer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Skin care interventions in infants for preventing eczema and food allergy.
Kelleher MM, Cro S, Cornelius V, Lodrup Carlsen KC, et al · · 2021 · cited 43× · PMID 33545739 · DOI 10.1002/14651858.cd013534.pub2
Skin care interventions in infants for preventing eczema and food allergy.
Kelleher MM, Phillips R, Brown SJ, Cro S, et al · · 2022 · cited 29× · PMID 36373988 · DOI 10.1002/14651858.cd013534.pub3

Verify or expand the search:

Other recruiting trials for Dermatitis, Atopic

Currently open trials in the same condition.

NCT07230860 — A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
NCT06899204 — Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate · recruiting
NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
NCT06881251 — A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) · Phase 2 · active not recruiting
NCT06554847 — Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis · Phase 3 · active not recruiting

Other MYOR Ltd. trials

Trials by the same sponsor.

NCT04573244 — Hemoglobin Easy Measurement With Optical Artificial Intelligence · completed
NCT04325451 — Comprehending Atopic Risk Elements · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03808532 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MYOR Ltd.
Last refreshed: 13 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03808532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing